IκB kinase regulation of the TPL‐2/ERK MAPK pathway

Summary:  Nuclear factor‐κB (NF‐κB) and mitogen‐activated protein kinase (MAPK) activation play central roles in the induction of gene expression in innate immune cells following pathogen recognition. TPL‐2 (tumor progression locus 2) is the MAP 3‐kinase component of an ERK‐1/2 (extracellular signal‐regulated kinase 1/2) MAPK pathway activated by Toll‐like receptor and tumor necrosis factor receptor family stimulation. In this review, we discuss results obtained from our laboratory and others that show that TPL‐2 signaling function is directly controlled by the inhibitor of NF‐κB (IκB) kinase (IKK) complex. Significantly, this means that IKK controls both NF‐κB and ERK activation. TPL‐2 is stoichiometrically complexed with the NF‐κB inhibitory protein, NF‐κB1 p105, and the ubiquitin‐binding protein ABIN‐2, both of which are required to maintain TPL‐2 protein stability. Binding to p105 also prevents TPL‐2 from phosphorylating MEK (MAPK/ERK kinase), its downstream target. Agonist stimulation releases TPL‐2 from p105‐inhibition by IKK‐mediated phosphorylation of p105, which triggers degradation of p105 by the proteasome. This facilitates TPL‐2 phosphorylation of MEK, in addition to liberating p105‐associated Rel subunits to translocate into the nucleus. We also examine evidence that TPL‐2 is critical for the induction of inflammation and may play a role in development and/or progression of certain types of cancer. Finally, we consider the potential of TPL‐2 as an anti‐inflammatory drug target for treatment of certain types of inflammatory disease and cancer.

[1]  Y. Ben-Neriah,et al.  Regulation of NF‐κB by ubiquitination and degradation of the IκBs , 2012, Immunological reviews.

[2]  M. Karin,et al.  NF‐κB and the link between inflammation and cancer , 2012, Immunological reviews.

[3]  P. Tsichlis,et al.  Tumor Progression Locus 2 Mediates Signal-Induced Increases in Cytoplasmic Calcium and Cell Migration , 2011, Science Signaling.

[4]  David R. Anderson,et al.  Discovery of indazoles as inhibitors of Tpl2 kinase. , 2011, Bioorganic & medicinal chemistry letters.

[5]  S. Alemany,et al.  Involvement of Cot activity in the proliferation of ALCL lymphoma cells. , 2011, Biochemical and biophysical research communications.

[6]  Michael Karin,et al.  Inflammation meets cancer, with NF-κB as the matchmaker , 2011, Nature Immunology.

[7]  A. Eliopoulos,et al.  Tpl2 kinase signal transduction in inflammation and cancer. , 2011, Cancer letters.

[8]  R. Lamb,et al.  Signalling by amino acid nutrients. , 2011, Biochemical Society transactions.

[9]  G. Shulman,et al.  Tumor Progression Locus 2 (TPL2) Regulates Obesity-Associated Inflammation and Insulin Resistance , 2011, Diabetes.

[10]  L. Staudt,et al.  A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. , 2011, Blood.

[11]  S. Ley,et al.  NF-κB1 Inhibits TLR-Induced IFN-β Production in Macrophages through TPL-2–Dependent ERK Activation , 2011, The Journal of Immunology.

[12]  J. Wiest,et al.  Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis , 2011, Oncogene.

[13]  W. Au,et al.  A20, ABIN-1/2, and CARD11 Mutations and Their Prognostic Value in Gastrointestinal Diffuse Large B-Cell Lymphoma , 2011, Clinical Cancer Research.

[14]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[15]  C. Moinard,et al.  TPL-2–Mediated Activation of MAPK Downstream of TLR4 Signaling Is Coupled to Arginine Availability , 2010, Science Signaling.

[16]  S. Morris,et al.  Arginine: Master and Commander in Innate Immune Responses , 2010, Science Signaling.

[17]  S. Knapp,et al.  Structural Comparison of Human Mammalian Ste20-Like Kinases , 2010, PloS one.

[18]  I. Amit,et al.  The phosphoproteome of toll-like receptor-activated macrophages , 2010, Molecular systems biology.

[19]  L. Staudt.  Oncogenic activation of NF-kappaB. , 2010, Cold Spring Harbor perspectives in biology.

[20]  S. Akira,et al.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors , 2010, Nature Immunology.

[21]  N. Chiba,et al.  Cot/Tpl2 regulates IL-23 p19 expression in LPS-stimulated macrophages through ERK activation , 2010, Journal of Physiology and Biochemistry.

[22]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[23]  Joshua F. McMichael,et al.  Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.

[24]  Yoshihiro Baba,et al.  B cell signaling and fate decision. , 2010, Annual review of immunology.

[25]  S. Smale.  Selective Transcription in Response to an Inflammatory Stimulus , 2010, Cell.

[26]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[27]  J. O’Shea,et al.  Tumor Progression Locus 2 (Map3k8) Is Critical for Host Defense against Listeria monocytogenes and IL-1β Production1 , 2009, The Journal of Immunology.

[28]  J. O’Shea,et al.  Ablation of Tumor Progression Locus 2 Promotes a Type 2 Th Cell Response in Ovalbumin-Immunized Mice , 2009, The Journal of Immunology.

[29]  P. Cohen,et al.  IRAK1-independent pathways required for the interleukin-1-stimulated activation of the Tpl2 catalytic subunit and its dissociation from ABIN2. , 2009, The Biochemical journal.

[30]  Ruslan Medzhitov,et al.  Transcriptional control of the inflammatory response , 2009, Nature Reviews Immunology.

[31]  G. Natoli,et al.  Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB , 2009, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Frank Kaiser,et al.  TPL-2 negatively regulates interferon-β production in macrophages and myeloid dendritic cells , 2009, The Journal of experimental medicine.

[33]  R. Beyaert,et al.  ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling. , 2009, Biochemical pharmacology.

[34]  Samy Lamouille,et al.  TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. , 2009, Molecular cell.

[35]  J. Stow,et al.  Cytokine secretion in macrophages and other cells: pathways and mediators. , 2009, Immunobiology.

[36]  A. Hoffmann,et al.  The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecular-weight heterogeneous complexes. , 2009, Molecular cell.

[37]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[38]  E. De Gregorio,et al.  Immunology of TLR-independent vaccine adjuvants. , 2009, Current opinion in immunology.

[39]  A. Salmeron,et al.  Cot/Tpl-2 protein kinase as a target for the treatment of inflammatory disease. , 2009, Current topics in medicinal chemistry.

[40]  David Komander,et al.  Molecular discrimination of structurally equivalent Lys 63‐linked and linear polyubiquitin chains , 2009, EMBO reports.

[41]  P. Cohen.  Targeting protein kinases for the development of anti-inflammatory drugs. , 2009, Current opinion in cell biology.

[42]  M. Rout,et al.  Cell structure and dynamics. , 2009, Current opinion in cell biology.

[43]  S. Gringhuis,et al.  Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-κB activation through Raf-1 and Syk , 2009, Nature Immunology.

[44]  B. Aggarwal,et al.  Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe , 2009, Clinical Cancer Research.

[45]  A. Sher,et al.  Tpl2 kinase regulates T cell interferon-γ production and host resistance to Toxoplasma gondii , 2008, The Journal of experimental medicine.

[46]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[47]  R. Dixon,et al.  Discovery of thieno[2,3-c]pyridines as potent COT inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[48]  V. Kuchroo,et al.  Induction and effector functions of TH17 cells , 2008, Nature.

[49]  T. Lawrence,et al.  “Re-educating” tumor-associated macrophages by targeting NF-κB , 2008, The Journal of experimental medicine.

[50]  M. Karin,et al.  An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation , 2008, The Journal of experimental medicine.

[51]  P. Tsichlis,et al.  Tpl2 and ERK transduce antiproliferative T cell receptor signals and inhibit transformation of chronically stimulated T cells , 2008, Proceedings of the National Academy of Sciences.

[52]  Philip R. Cohen,et al.  TPL2-mediated activation of ERK1 and ERK2 regulates the processing of pre-TNFα in LPS-stimulated macrophages , 2008, Journal of Cell Science.

[53]  K. Seidl,et al.  Pharmacologic Inhibition of Tpl2 Blocks Inflammatory Responses in Primary Human Monocytes, Synoviocytes, and Blood* , 2007, Journal of Biological Chemistry.

[54]  M. Neuenhahn,et al.  NF-κB Is a Negative Regulator of IL-1β Secretion as Revealed by Genetic and Pharmacological Inhibition of IKKβ , 2007, Cell.

[55]  P. Tsichlis,et al.  Phosphorylation of TPL-2 on Serine 400 Is Essential for Lipopolysaccharide Activation of Extracellular Signal-Regulated Kinase in Macrophages , 2007, Molecular and Cellular Biology.

[56]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[57]  M. Ivan,et al.  Characterization of phosphorylation sites on Tpl2 using IMAC enrichment and a linear ion trap mass spectrometer. , 2007, Journal of proteome research.

[58]  Richa Agarwala,et al.  COBALT: constraint-based alignment tool for multiple protein sequences , 2007, Bioinform..

[59]  P. Khavari,et al.  Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. , 2007, Developmental cell.

[60]  Yonghan Hu.  Inhibition of Tpl2 Kinase and TNFα Production with Quinoline‐3‐carbonitriles for the Treatment of Rheumatoid Arthritis. , 2007 .

[61]  J. Telliez,et al.  Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. , 2006, Bioorganic & medicinal chemistry letters.

[62]  A. Sica,et al.  p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. , 2006, Cancer research.

[63]  S. Akira,et al.  Toll-like receptors and innate immunity , 2006, Journal of Molecular Medicine.

[64]  P. Cohen,et al.  Interleukin‐1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62 , 2006, FEBS letters.

[65]  Shao-Cong Sun,et al.  Deregulated Activation of Oncoprotein Kinase Tpl2/Cot in HTLV-I-transformed T Cells* , 2006, Journal of Biological Chemistry.

[66]  D. Kioussis,et al.  ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses , 2006, Nature Immunology.

[67]  Steve Gerondakis,et al.  Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Shao-Cong Sun,et al.  Phosphorylation of NF-kappaB1/p105 by oncoprotein kinase Tpl2: implications for a novel mechanism of Tpl2 regulation. , 2006, Biochimica et biophysica acta.

[69]  M. Gadjeva,et al.  Defective Activation of ERK in Macrophages Lacking the p50/p105 Subunit of NF-κB Is Responsible for Elevated Expression of IL-12 p40 Observed after Challenge with Helicobacter hepaticus1 , 2006, The Journal of Immunology.

[70]  Kevin M. Clark,et al.  Purification and kinetic characterization of recombinant human mitogen-activated protein kinase kinase kinase COT and the complexes with its cellular partner NF-kappa B1 p105. , 2005, Archives of biochemistry and biophysics.

[71]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[72]  Jeonghee Cho,et al.  Tpl2/Cot Signals Activate ERK, JNK, and NF-κB in a Cell-type and Stimulus-specific Manner* , 2005, Journal of Biological Chemistry.

[73]  S. Soond,et al.  ERK-mediated phosphorylation of Thr735 in TNFα-converting enzyme and its potential role in TACE protein trafficking , 2005, Journal of Cell Science.

[74]  Jeonghee Cho,et al.  Tpl2 (Tumor Progression Locus 2) Phosphorylation at Thr290 Is Induced by Lipopolysaccharide via an Iκ-B Kinase-β-dependent Pathway and Is Required for Tpl2 Activation by External Signals* , 2005, Journal of Biological Chemistry.

[75]  Jeonghee Cho,et al.  Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Cuozzo,et al.  Phosphorylation of Threonine 290 in the Activation Loop of Tpl2/Cot Is Necessary but Not Sufficient for Kinase Activity* , 2004, Journal of Biological Chemistry.

[77]  C. Tsatsanis,et al.  Expression of the Tpl2/Cot oncogene in human T-cell neoplasias , 2004, Molecular Cancer.

[78]  M. Robinson,et al.  Kinase Mitogen-activated Protein Kinase Tpl-2/mek/extracellular Signal-regulated Lipopolysaccharide Activation of the Supplemental Material , 2004 .

[79]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[80]  Marshall W. Anderson,et al.  Mutational activation of the MAP3K8 protooncogene in lung cancer , 2004, Genes, chromosomes & cancer.

[81]  A. Masuda,et al.  A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell differentiation. , 2004, The Journal of clinical investigation.

[82]  Susan S. Taylor,et al.  Regulation of protein kinases; controlling activity through activation segment conformation. , 2004, Molecular cell.

[83]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[84]  Shao-Cong Sun,et al.  IκB Kinase Is an Essential Component of the Tpl2 Signaling Pathway , 2004, Molecular and Cellular Biology.

[85]  S. Howell,et al.  ABIN-2 Forms a Ternary Complex with TPL-2 and NF-κB1 p105 and Is Essential for TPL-2 Protein Stability , 2004, Molecular and Cellular Biology.

[86]  S. Alemany,et al.  The COOH-Terminal Domain of Wild-Type Cot Regulates Its Stability and Kinase Specific Activity , 2003, Molecular and Cellular Biology.

[87]  C. Dumitru,et al.  Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40 , 2003, The EMBO journal.

[88]  S. Smerdon,et al.  NF-κB1 p105 Negatively Regulates TPL-2 MEK Kinase Activity , 2003, Molecular and Cellular Biology.

[89]  D. Cantrell.  GTPases and T cell activation , 2003, Immunological reviews.

[90]  Shao-Cong Sun,et al.  NF-kappaB1/p105 regulates lipopolysaccharide-stimulated MAP kinase signaling by governing the stability and function of the Tpl2 kinase. , 2003, Molecular cell.

[91]  R. Hay,et al.  βTrCP-Mediated Proteolysis of NF-κB1 p105 Requires Phosphorylation of p105 Serines 927 and 932 , 2003, Molecular and Cellular Biology.

[92]  G. Kollias,et al.  Genetic Dissection of the Cellular Pathways and Signaling Mechanisms in Modeled Tumor Necrosis Factor–induced Crohn's-like Inflammatory Bowel Disease , 2002, The Journal of experimental medicine.

[93]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[94]  Brian A. Hemmings,et al.  Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP , 2002, Nature Structural Biology.

[95]  C. Turck,et al.  Akt-Dependent Phosphorylation Specifically Regulates Cot Induction of NF-κB-Dependent Transcription , 2002, Molecular and Cellular Biology.

[96]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[97]  L. Young,et al.  The Oncogenic Protein Kinase Tpl-2/Cot Contributes to Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1-Induced NF-κB Signaling Downstream of TRAF2 , 2002, Journal of Virology.

[98]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[99]  J. Adams,et al.  Kinetic and catalytic mechanisms of protein kinases. , 2001, Chemical reviews.

[100]  A. Salmeron,et al.  Direct Phosphorylation of NF-κB1 p105 by the IκB Kinase Complex on Serine 927 Is Essential for Signal-induced p105 Proteolysis* , 2001, The Journal of Biological Chemistry.

[101]  G. Kollias,et al.  TNF-α Induction by LPS Is Regulated Posttranscriptionally via a Tpl2/ERK-Dependent Pathway , 2000, Cell.

[102]  L. Glimcher,et al.  Lineage commitment in the immune system: the T helper lymphocyte grows up. , 2000, Genes & development.

[103]  A. Ciechanover,et al.  SCFβ‐TrCP ubiquitin ligase‐mediated processing of NF‐κB p 105 requires phosphorylation of its C‐terminus by IκB kinase , 2000 .

[104]  J. Gutkind,et al.  Multiple Mitogen-Activated Protein Kinase Signaling Pathways Connect the Cot Oncoprotein to the c-junPromoter and to Cellular Transformation , 2000, Molecular and Cellular Biology.

[105]  A. Sher,et al.  Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. , 1999, Immunobiology.

[106]  G. Sourvinos,et al.  Overexpression of the Tpl-2/Cot oncogene in human breast cancer , 1999, Oncogene.

[107]  C. Scheidereit,et al.  NF‐κB p105 is a target of IκB kinases and controls signal induction of Bcl‐3–p50 complexes , 1999 .

[108]  G. Kollias,et al.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.

[109]  J. Troppmair,et al.  Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells , 1999, Oncogene.

[110]  L. Johnston,et al.  TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105 , 1999, Nature.

[111]  N. Copeland,et al.  Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. , 1997, Genes & development.

[112]  J. Peli,et al.  Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis. , 1996, Oncogene.

[113]  D. Pappin,et al.  Activation of MEK‐1 and SEK‐1 by Tpl‐2 proto‐oncoprotein, a novel MAP kinase kinase kinase. , 1996, The EMBO journal.

[114]  C. Marshall,et al.  MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. , 1994, Current opinion in genetics & development.

[115]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[116]  R. Zinkernagel,et al.  Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes , 1993, Nature.

[117]  P. Højrup,et al.  Rapid identification of proteins by peptide-mass fingerprinting , 1993, Current Biology.

[118]  P. Tsichlis,et al.  Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[119]  L. Moldawer,et al.  Type I IL-1 receptor blockade exacerbates murine listeriosis. , 1992, Journal of immunology.

[120]  E. Unanue,et al.  Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[121]  J. Miyoshi,et al.  Structure and transforming potential of the human cot oncogene encoding a putative protein kinase , 1991, Molecular and cellular biology.

[122]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[123]  S. Ley,et al.  Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase , 2011, Cell Research.

[124]  L. Boscá,et al.  Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: implications for NO synthase 2 expression , 2011 .

[125]  George Kollias,et al.  Cellular mechanisms of TNF function in models of inflammation and autoimmunity. , 2010, Current directions in autoimmunity.

[126]  L. Staudt.  Oncogenic Activation of NF- k B , 2010 .

[127]  Samy Lamouille,et al.  TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling , 2009 .

[128]  V. Strand,et al.  Biologic therapies in rheumatology: lessons learned, future directions , 2007, Nature Reviews Drug Discovery.

[129]  Pamela N. Munster,et al.  IN HUMAN BREAST CANCER , 2007 .

[130]  S. Ley,et al.  MAP kinase kinase kinases and innate immunity. , 2006, Trends in immunology.

[131]  Michael Karin,et al.  The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.

[132]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.